nodes	percent_of_prediction	percent_of_DWPC	metapath
Vigabatrin—GABBR1—cardiac ventricle—dilated cardiomyopathy	0.0211	0.308	CbGeAlD
Vigabatrin—Cerebration impaired—Furosemide—dilated cardiomyopathy	0.0182	0.0217	CcSEcCtD
Vigabatrin—GABBR1—Inwardly rectifying K+ channels—ABCC9—dilated cardiomyopathy	0.0179	0.188	CbGpPWpGaD
Vigabatrin—Apathy—Furosemide—dilated cardiomyopathy	0.015	0.0179	CcSEcCtD
Vigabatrin—Ear disorder—Lisinopril—dilated cardiomyopathy	0.0149	0.0177	CcSEcCtD
Vigabatrin—Flat affect—Furosemide—dilated cardiomyopathy	0.0148	0.0177	CcSEcCtD
Vigabatrin—Lethargy—Spironolactone—dilated cardiomyopathy	0.0145	0.0174	CcSEcCtD
Vigabatrin—Cholestasis—Furosemide—dilated cardiomyopathy	0.0141	0.0168	CcSEcCtD
Vigabatrin—GABBR1—heart—dilated cardiomyopathy	0.0139	0.202	CbGeAlD
Vigabatrin—Ataxia—Spironolactone—dilated cardiomyopathy	0.0134	0.016	CcSEcCtD
Vigabatrin—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.0128	0.0153	CcSEcCtD
Vigabatrin—Laryngeal oedema—Lisinopril—dilated cardiomyopathy	0.0125	0.0149	CcSEcCtD
Vigabatrin—Disturbance in attention—Furosemide—dilated cardiomyopathy	0.0123	0.0147	CcSEcCtD
Vigabatrin—GABBR1—cardiac atrium—dilated cardiomyopathy	0.0118	0.173	CbGeAlD
Vigabatrin—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.0113	0.0136	CcSEcCtD
Vigabatrin—Drowsiness—Spironolactone—dilated cardiomyopathy	0.011	0.0131	CcSEcCtD
Vigabatrin—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.0109	0.013	CcSEcCtD
Vigabatrin—SLC36A1—heart—dilated cardiomyopathy	0.0109	0.159	CbGeAlD
Vigabatrin—ABAT—heart—dilated cardiomyopathy	0.0108	0.158	CbGeAlD
Vigabatrin—Otitis media—Lisinopril—dilated cardiomyopathy	0.0103	0.0123	CcSEcCtD
Vigabatrin—Memory impairment—Lisinopril—dilated cardiomyopathy	0.0102	0.0122	CcSEcCtD
Vigabatrin—Endocrine disorder—Lisinopril—dilated cardiomyopathy	0.00967	0.0116	CcSEcCtD
Vigabatrin—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00932	0.0111	CcSEcCtD
Vigabatrin—Mental disability—Furosemide—dilated cardiomyopathy	0.00927	0.0111	CcSEcCtD
Vigabatrin—Viral infection—Lisinopril—dilated cardiomyopathy	0.00887	0.0106	CcSEcCtD
Vigabatrin—Arthropathy—Lisinopril—dilated cardiomyopathy	0.00882	0.0105	CcSEcCtD
Vigabatrin—Vascular purpura—Furosemide—dilated cardiomyopathy	0.00867	0.0104	CcSEcCtD
Vigabatrin—Deafness—Furosemide—dilated cardiomyopathy	0.00867	0.0104	CcSEcCtD
Vigabatrin—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00825	0.00986	CcSEcCtD
Vigabatrin—Thirst—Furosemide—dilated cardiomyopathy	0.00815	0.00974	CcSEcCtD
Vigabatrin—Purpura—Furosemide—dilated cardiomyopathy	0.00805	0.00962	CcSEcCtD
Vigabatrin—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00802	0.00958	CcSEcCtD
Vigabatrin—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00796	0.00952	CcSEcCtD
Vigabatrin—Lethargy—Furosemide—dilated cardiomyopathy	0.00791	0.00946	CcSEcCtD
Vigabatrin—Salivary hypersecretion—Lisinopril—dilated cardiomyopathy	0.00778	0.0093	CcSEcCtD
Vigabatrin—Malaise—Spironolactone—dilated cardiomyopathy	0.00774	0.00925	CcSEcCtD
Vigabatrin—Irritability—Furosemide—dilated cardiomyopathy	0.0074	0.00885	CcSEcCtD
Vigabatrin—Discomfort—Spironolactone—dilated cardiomyopathy	0.00722	0.00863	CcSEcCtD
Vigabatrin—Confusional state—Spironolactone—dilated cardiomyopathy	0.00706	0.00844	CcSEcCtD
Vigabatrin—GABBR1—Potassium Channels—ABCC9—dilated cardiomyopathy	0.00706	0.0744	CbGpPWpGaD
Vigabatrin—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00703	0.0084	CcSEcCtD
Vigabatrin—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00698	0.00835	CcSEcCtD
Vigabatrin—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00675	0.00806	CcSEcCtD
Vigabatrin—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.00639	0.00763	CcSEcCtD
Vigabatrin—Somnolence—Spironolactone—dilated cardiomyopathy	0.00623	0.00744	CcSEcCtD
Vigabatrin—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00605	0.00723	CcSEcCtD
Vigabatrin—Drowsiness—Furosemide—dilated cardiomyopathy	0.00598	0.00714	CcSEcCtD
Vigabatrin—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00593	0.00708	CcSEcCtD
Vigabatrin—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00582	0.00695	CcSEcCtD
Vigabatrin—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00582	0.00695	CcSEcCtD
Vigabatrin—Diplopia—Lisinopril—dilated cardiomyopathy	0.00582	0.00695	CcSEcCtD
Vigabatrin—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00577	0.0069	CcSEcCtD
Vigabatrin—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00565	0.00676	CcSEcCtD
Vigabatrin—Face oedema—Lisinopril—dilated cardiomyopathy	0.00562	0.00671	CcSEcCtD
Vigabatrin—Urticaria—Spironolactone—dilated cardiomyopathy	0.00557	0.00665	CcSEcCtD
Vigabatrin—Irritability—Lisinopril—dilated cardiomyopathy	0.00555	0.00664	CcSEcCtD
Vigabatrin—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00554	0.00662	CcSEcCtD
Vigabatrin—Ataxia—Lisinopril—dilated cardiomyopathy	0.00547	0.00654	CcSEcCtD
Vigabatrin—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00526	0.00628	CcSEcCtD
Vigabatrin—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.00524	0.00626	CcSEcCtD
Vigabatrin—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.0052	0.00622	CcSEcCtD
Vigabatrin—Visual impairment—Furosemide—dilated cardiomyopathy	0.00517	0.00618	CcSEcCtD
Vigabatrin—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00516	0.00617	CcSEcCtD
Vigabatrin—GABBR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.00513	0.0541	CbGpPWpGaD
Vigabatrin—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00507	0.00606	CcSEcCtD
Vigabatrin—Influenza—Lisinopril—dilated cardiomyopathy	0.00503	0.00601	CcSEcCtD
Vigabatrin—Eye disorder—Furosemide—dilated cardiomyopathy	0.00501	0.00599	CcSEcCtD
Vigabatrin—Tinnitus—Furosemide—dilated cardiomyopathy	0.005	0.00598	CcSEcCtD
Vigabatrin—Pruritus—Spironolactone—dilated cardiomyopathy	0.00496	0.00592	CcSEcCtD
Vigabatrin—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00484	0.00578	CcSEcCtD
Vigabatrin—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00479	0.00573	CcSEcCtD
Vigabatrin—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00467	0.00559	CcSEcCtD
Vigabatrin—Malnutrition—Furosemide—dilated cardiomyopathy	0.00467	0.00558	CcSEcCtD
Vigabatrin—Dizziness—Spironolactone—dilated cardiomyopathy	0.00463	0.00554	CcSEcCtD
Vigabatrin—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00463	0.00554	CcSEcCtD
Vigabatrin—Weight increased—Lisinopril—dilated cardiomyopathy	0.00458	0.00547	CcSEcCtD
Vigabatrin—ABAT—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00453	0.0478	CbGpPWpGaD
Vigabatrin—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00451	0.00539	CcSEcCtD
Vigabatrin—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00449	0.00537	CcSEcCtD
Vigabatrin—Depression—Lisinopril—dilated cardiomyopathy	0.00447	0.00534	CcSEcCtD
Vigabatrin—Vomiting—Spironolactone—dilated cardiomyopathy	0.00445	0.00532	CcSEcCtD
Vigabatrin—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00445	0.00531	CcSEcCtD
Vigabatrin—Rash—Spironolactone—dilated cardiomyopathy	0.00442	0.00528	CcSEcCtD
Vigabatrin—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00441	0.00527	CcSEcCtD
Vigabatrin—Vision blurred—Furosemide—dilated cardiomyopathy	0.0044	0.00526	CcSEcCtD
Vigabatrin—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.0044	0.00525	CcSEcCtD
Vigabatrin—Headache—Spironolactone—dilated cardiomyopathy	0.00439	0.00525	CcSEcCtD
Vigabatrin—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00436	0.00521	CcSEcCtD
Vigabatrin—Anaemia—Furosemide—dilated cardiomyopathy	0.00432	0.00516	CcSEcCtD
Vigabatrin—Agitation—Furosemide—dilated cardiomyopathy	0.00429	0.00513	CcSEcCtD
Vigabatrin—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00424	0.00507	CcSEcCtD
Vigabatrin—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00421	0.00503	CcSEcCtD
Vigabatrin—Vertigo—Furosemide—dilated cardiomyopathy	0.0042	0.00501	CcSEcCtD
Vigabatrin—Nausea—Spironolactone—dilated cardiomyopathy	0.00416	0.00497	CcSEcCtD
Vigabatrin—Hallucination—Lisinopril—dilated cardiomyopathy	0.00401	0.00479	CcSEcCtD
Vigabatrin—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00397	0.00474	CcSEcCtD
Vigabatrin—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00395	0.00472	CcSEcCtD
Vigabatrin—GABBR1—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00385	0.0407	CbGpPWpGaD
Vigabatrin—Confusional state—Furosemide—dilated cardiomyopathy	0.00384	0.00459	CcSEcCtD
Vigabatrin—SLC36A1—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00383	0.0404	CbGpPWpGaD
Vigabatrin—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00381	0.00455	CcSEcCtD
Vigabatrin—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00375	0.00449	CcSEcCtD
Vigabatrin—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00374	0.00447	CcSEcCtD
Vigabatrin—Skin disorder—Furosemide—dilated cardiomyopathy	0.0037	0.00442	CcSEcCtD
Vigabatrin—ABAT—Neuronal System—ABCC9—dilated cardiomyopathy	0.00362	0.0382	CbGpPWpGaD
Vigabatrin—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00353	0.00421	CcSEcCtD
Vigabatrin—Malnutrition—Lisinopril—dilated cardiomyopathy	0.0035	0.00419	CcSEcCtD
Vigabatrin—ABAT—Neuronal System—ACTN2—dilated cardiomyopathy	0.00347	0.0366	CbGpPWpGaD
Vigabatrin—Tension—Lisinopril—dilated cardiomyopathy	0.00344	0.00411	CcSEcCtD
Vigabatrin—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00342	0.00409	CcSEcCtD
Vigabatrin—Nervousness—Lisinopril—dilated cardiomyopathy	0.0034	0.00407	CcSEcCtD
Vigabatrin—Back pain—Lisinopril—dilated cardiomyopathy	0.00339	0.00405	CcSEcCtD
Vigabatrin—Somnolence—Furosemide—dilated cardiomyopathy	0.00339	0.00405	CcSEcCtD
Vigabatrin—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00337	0.00403	CcSEcCtD
Vigabatrin—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00331	0.00396	CcSEcCtD
Vigabatrin—Vision blurred—Lisinopril—dilated cardiomyopathy	0.0033	0.00395	CcSEcCtD
Vigabatrin—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00329	0.00393	CcSEcCtD
Vigabatrin—Fatigue—Furosemide—dilated cardiomyopathy	0.00329	0.00393	CcSEcCtD
Vigabatrin—Tremor—Lisinopril—dilated cardiomyopathy	0.00328	0.00392	CcSEcCtD
Vigabatrin—Constipation—Furosemide—dilated cardiomyopathy	0.00326	0.0039	CcSEcCtD
Vigabatrin—Pain—Furosemide—dilated cardiomyopathy	0.00326	0.0039	CcSEcCtD
Vigabatrin—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00325	0.00389	CcSEcCtD
Vigabatrin—Anaemia—Lisinopril—dilated cardiomyopathy	0.00324	0.00387	CcSEcCtD
Vigabatrin—Angioedema—Lisinopril—dilated cardiomyopathy	0.0032	0.00383	CcSEcCtD
Vigabatrin—Malaise—Lisinopril—dilated cardiomyopathy	0.00316	0.00378	CcSEcCtD
Vigabatrin—Vertigo—Lisinopril—dilated cardiomyopathy	0.00315	0.00376	CcSEcCtD
Vigabatrin—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00314	0.00375	CcSEcCtD
Vigabatrin—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00312	0.00373	CcSEcCtD
Vigabatrin—GABBR1—Neuronal System—ABCC9—dilated cardiomyopathy	0.00308	0.0325	CbGpPWpGaD
Vigabatrin—Cough—Lisinopril—dilated cardiomyopathy	0.00306	0.00365	CcSEcCtD
Vigabatrin—Urticaria—Furosemide—dilated cardiomyopathy	0.00303	0.00362	CcSEcCtD
Vigabatrin—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00301	0.0036	CcSEcCtD
Vigabatrin—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00301	0.0036	CcSEcCtD
Vigabatrin—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00298	0.00357	CcSEcCtD
Vigabatrin—Chest pain—Lisinopril—dilated cardiomyopathy	0.00298	0.00357	CcSEcCtD
Vigabatrin—Myalgia—Lisinopril—dilated cardiomyopathy	0.00298	0.00357	CcSEcCtD
Vigabatrin—Anxiety—Lisinopril—dilated cardiomyopathy	0.00297	0.00355	CcSEcCtD
Vigabatrin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00296	0.00354	CcSEcCtD
Vigabatrin—GABBR1—Neuronal System—ACTN2—dilated cardiomyopathy	0.00295	0.0312	CbGpPWpGaD
Vigabatrin—Discomfort—Lisinopril—dilated cardiomyopathy	0.00295	0.00352	CcSEcCtD
Vigabatrin—Confusional state—Lisinopril—dilated cardiomyopathy	0.00288	0.00345	CcSEcCtD
Vigabatrin—Oedema—Lisinopril—dilated cardiomyopathy	0.00286	0.00342	CcSEcCtD
Vigabatrin—Infection—Lisinopril—dilated cardiomyopathy	0.00284	0.0034	CcSEcCtD
Vigabatrin—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00281	0.00336	CcSEcCtD
Vigabatrin—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00278	0.00332	CcSEcCtD
Vigabatrin—Asthenia—Furosemide—dilated cardiomyopathy	0.00273	0.00327	CcSEcCtD
Vigabatrin—Pruritus—Furosemide—dilated cardiomyopathy	0.0027	0.00322	CcSEcCtD
Vigabatrin—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00261	0.00312	CcSEcCtD
Vigabatrin—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00261	0.00311	CcSEcCtD
Vigabatrin—Insomnia—Lisinopril—dilated cardiomyopathy	0.00259	0.00309	CcSEcCtD
Vigabatrin—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00257	0.00307	CcSEcCtD
Vigabatrin—Somnolence—Lisinopril—dilated cardiomyopathy	0.00254	0.00304	CcSEcCtD
Vigabatrin—Dizziness—Furosemide—dilated cardiomyopathy	0.00252	0.00301	CcSEcCtD
Vigabatrin—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00252	0.00301	CcSEcCtD
Vigabatrin—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00249	0.00297	CcSEcCtD
Vigabatrin—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00247	0.00295	CcSEcCtD
Vigabatrin—Fatigue—Lisinopril—dilated cardiomyopathy	0.00247	0.00295	CcSEcCtD
Vigabatrin—Pain—Lisinopril—dilated cardiomyopathy	0.00245	0.00292	CcSEcCtD
Vigabatrin—Constipation—Lisinopril—dilated cardiomyopathy	0.00245	0.00292	CcSEcCtD
Vigabatrin—Vomiting—Furosemide—dilated cardiomyopathy	0.00242	0.0029	CcSEcCtD
Vigabatrin—Rash—Furosemide—dilated cardiomyopathy	0.0024	0.00287	CcSEcCtD
Vigabatrin—Dermatitis—Furosemide—dilated cardiomyopathy	0.0024	0.00287	CcSEcCtD
Vigabatrin—Headache—Furosemide—dilated cardiomyopathy	0.00239	0.00285	CcSEcCtD
Vigabatrin—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00236	0.00282	CcSEcCtD
Vigabatrin—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00234	0.0028	CcSEcCtD
Vigabatrin—Urticaria—Lisinopril—dilated cardiomyopathy	0.00227	0.00272	CcSEcCtD
Vigabatrin—Nausea—Furosemide—dilated cardiomyopathy	0.00226	0.00271	CcSEcCtD
Vigabatrin—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00226	0.0027	CcSEcCtD
Vigabatrin—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00226	0.0027	CcSEcCtD
Vigabatrin—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00211	0.00252	CcSEcCtD
Vigabatrin—GABBR1—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.00205	0.0217	CbGpPWpGaD
Vigabatrin—GABBR1—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.00205	0.0217	CbGpPWpGaD
Vigabatrin—Asthenia—Lisinopril—dilated cardiomyopathy	0.00205	0.00245	CcSEcCtD
Vigabatrin—Pruritus—Lisinopril—dilated cardiomyopathy	0.00202	0.00242	CcSEcCtD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.002	0.0211	CbGpPWpGaD
Vigabatrin—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00196	0.00234	CcSEcCtD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00195	0.0205	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00195	0.0205	CbGpPWpGaD
Vigabatrin—GABBR1—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.00191	0.0201	CbGpPWpGaD
Vigabatrin—Dizziness—Lisinopril—dilated cardiomyopathy	0.00189	0.00226	CcSEcCtD
Vigabatrin—Vomiting—Lisinopril—dilated cardiomyopathy	0.00182	0.00217	CcSEcCtD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00181	0.0191	CbGpPWpGaD
Vigabatrin—Rash—Lisinopril—dilated cardiomyopathy	0.0018	0.00216	CcSEcCtD
Vigabatrin—Dermatitis—Lisinopril—dilated cardiomyopathy	0.0018	0.00215	CcSEcCtD
Vigabatrin—Headache—Lisinopril—dilated cardiomyopathy	0.00179	0.00214	CcSEcCtD
Vigabatrin—Nausea—Lisinopril—dilated cardiomyopathy	0.0017	0.00203	CcSEcCtD
Vigabatrin—GABBR1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00124	0.0131	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00124	0.0131	CbGpPWpGaD
Vigabatrin—GABBR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.00117	0.0123	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00116	0.0122	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.00112	0.0118	CbGpPWpGaD
Vigabatrin—GABBR1—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.00111	0.0117	CbGpPWpGaD
Vigabatrin—ABAT—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.00103	0.0109	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000955	0.0101	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000906	0.00956	CbGpPWpGaD
Vigabatrin—GABBR1—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000877	0.00925	CbGpPWpGaD
Vigabatrin—ABAT—Neuronal System—RAF1—dilated cardiomyopathy	0.00079	0.00834	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000702	0.00741	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000702	0.00741	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000672	0.00709	CbGpPWpGaD
Vigabatrin—GABBR1—Neuronal System—RAF1—dilated cardiomyopathy	0.000672	0.00709	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000653	0.00689	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000638	0.00673	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000638	0.00673	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000632	0.00667	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000593	0.00625	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000574	0.00606	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.00054	0.0057	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000512	0.0054	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.00049	0.00517	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000465	0.00491	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000424	0.00448	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000398	0.0042	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000395	0.00417	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.00038	0.00401	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000377	0.00397	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000377	0.00397	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000361	0.00381	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.00035	0.00369	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000345	0.00364	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000339	0.00358	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.00029	0.00306	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000275	0.0029	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000239	0.00253	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000236	0.00249	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000213	0.00225	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—AGT—dilated cardiomyopathy	0.000204	0.00215	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000164	0.00173	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000141	0.00149	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—EGFR—dilated cardiomyopathy	9.7e-05	0.00102	CbGpPWpGaD
